Cielo Cinthya Calderon-Hernandez

Cielo Cinthya Calderon-Hernandez

Auto-generated profile, based on publicly available information

Cielo Cinthya Calderon-Hernandez

CHANGE Research Working Group, Universidad Científica del Sur, Lima 15067, Peru

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RCRuth Angélica Rojas De la cruz
Ruth Angélica Rojas De la cruz
JFJaneth Marbis Flores-Cordova
Janeth Marbis Flores-Cordova
CCCielo Cinthya Calderon-Hernandez
Cielo Cinthya Calderon-Hernandez
NCNelson Luis Cahuapaza-Gutierrez
Nelson Luis Cahuapaza-Gutierrez
NRNino Arturo Ccallalli Ruíz
Nino Arturo Ccallalli Ruíz
FRFernando M. Runzer-Colmenares
Fernando M. Runzer-Colmenares
Background: Evidence on the humoral and cellular immune responses to SARS-CoV-2 following COVID-19 vaccination in older adults is warranted. Aims: To synthesize and analyze the current evidence on humoral and cellular immune responses to both standard and booster COVID-19 vaccination in individuals aged 60 years and older. Methods: Clinical trials and observational studies were included. Reviews, case series, letters to the editor, and similar publications were excluded. A selective literature search was conducted in the following databases: PubMed, Scopus, EMBASE, and Web of Science. The risk of bias and methodological quality of the included studies were assessed using the Newcastle–Ottawa Scale (NOS) and the Risk of Bias 2.0 (RoB 2) tool. Statistical analysis was conducted using Stata version 18 and Review Manager version 5.4.1. Results: Thirteen studies were included: eleven observational studies and two randomized clinical trials, evaluating humoral and cellular immune responses in 782 older adults. Messenger RNA vaccines were the most administered, particularly Pfizer-BioNTech (76.9%) and Moderna mRNA-1273 (23%). In most cases, immune responses were assessed after the second dose and booster doses. Most studies (61.5%) reported increased IgG titers specific to the SARS-CoV-2 Spike protein, while 23.1% reported a decrease. Regarding cellular immunity, 46.2% of the studies reported low interferon-gamma (IFN-γ) levels post-vaccination, whereas 38.5% showed increases. These findings highlight the need for tailored vaccination strategies to address emerging variants, particularly in vulnerable populations such as older adults. Conclusions: In older adults receiving COVID-19 vaccination, humoral immunity tends to increase, whereas cellular responses are frequently diminished, reflecting age-related immunosenescence that may limit the durability and breadth of protection following vaccination in older adults.

26 November 2025 in Future Internet
Verified
Journal Article
Open access
PDF file
FRFernando M. Runzer-Colmenares
Fernando M. Runzer-Colmenares
NCNelson Luis Cahuapaza-Gutierrez
Nelson Luis Cahuapaza-Gutierrez
CCCielo Cinthya Calderon-Hernandez
Cielo Cinthya Calderon-Hernandez
CMChristian Loret de Mola
Christian Loret de Mola
Facial expression analysis using artificial intelligence (AI) represents an emerging approach for assessing mental health, particularly in neurocognitive disorders. This study encompassed observational investigations that assessed facial expressions in individuals aged 60 years and above. A comprehensive literature search was carried out across PubMed, Scopus, EMBASE, and Web of Science. Risk of bias and study quality were assessed using the QUADAS-2 and CLAIM tools. Descriptive analysis and meta-analysis of proportions were performed using STATA version 19. The pooled effect size (ES) was calculated using a random-effects model (DerSimonian–Laird method), and results were presented with corresponding 95% confidence intervals (CI). Six studies were analyzed, comprising a total of 433 participants aged over 60 years, representing diverse AI applications in the detection of neurocognitive disorders. The disorders evaluated included mild cognitive impairment (MCI) (37.4%), dementia (29.3%), and Alzheimer’s disease (AD) (33.3%). Most studies (83.3%) used video-based facial recordings analyzed through deep learning algorithms and emotion recognition models. The pooled meta-analysis demonstrated that AI-based facial recognition algorithms achieved a high overall detection accuracy in older adults (ES = 0.84; 95% CI: 0.77–0.91), with the best performance observed in Alzheimer’s disease (ES = 0.93; 95% CI: 0.89–0.97). AI-based facial analysis demonstrates high, robust, and non-invasive accuracy for the early and differential detection of neurocognitive disorders, including MCI, dementia-related conditions, and AD, in older adults.

22 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
FRFernando M. Runzer-Colmenares
Fernando M. Runzer-Colmenares
NCNelson Luis Cahuapaza-Gutierrez
Nelson Luis Cahuapaza-Gutierrez
CCCielo Cinthya Calderon-Hernandez
Cielo Cinthya Calderon-Hernandez
CHCamila Marjory Hilares-Jorge
Camila Marjory Hilares-Jorge
Background/Objectives: Neurocognitive disorders represent a growing burden among older adults. Although respiratory vaccines have demonstrated efficacy and safety in preventing acute respiratory events, their potential impact on the development of chronic neurocognitive disorders, such as cognitive impairment, dementia, and Alzheimer’s disease (AD), has not been extensively explored. The objective of this scoping review was to synthesize and analyze the available evidence on the association between respiratory vaccination and the risk of developing cognitive impairment, dementia, and Alzheimer’s disease. Methods: A scoping review was conducted in accordance with the PRISMA-ScR guidelines. A literature search was performed in the PubMed, Scopus, and Web of Science databases through 15 June 2026. Studies involving older adults (≥60 years), irrespective of their baseline neurocognitive status, were included. Observational studies (cohort and case–control studies) were considered. Editorials, narrative reviews, and other non-original articles were excluded. Results: Eighteen studies were included, with cohort studies being the predominant design. Four main categories of respiratory vaccines were evaluated: influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal vaccines, in relation to the risk of cognitive impairment, dementia, and AD. Influenza vaccination was associated with a lower risk of dementia and AD, with a potential dose–response relationship observed, whereby a greater number of vaccinations was associated with a greater reduction in risk. Pneumococcal vaccination was also associated with a lower risk of dementia and AD, particularly among individuals who received a greater number of vaccine doses. In contrast, the evidence regarding COVID-19 and RSV vaccines was limited and yielded heterogeneous findings. Conclusions: Influenza and pneumococcal vaccination maybe associated with a lower risk of Alzheimer’s disease and dementia. However, the evidence regarding COVID-19 and RSV vaccines remains limited, and additional studies are needed to clarify their impact on the risk of developing neurocognitive disorders.

20 March 2026 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
NCNelson Luis Cahuapaza-Gutierrez
Nelson Luis Cahuapaza-Gutierrez
CCCielo Cinthya Calderon-Hernandez
Cielo Cinthya Calderon-Hernandez
MBMariam Miyanay Umeres Bravo
Mariam Miyanay Umeres Bravo
TVTatiana Vanessa Villavicencio-Escudero
Tatiana Vanessa Villavicencio-Escudero

3 July 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
NCNelson Luis Cahuapaza-Gutierrez
Nelson Luis Cahuapaza-Gutierrez
CCCielo Cinthya Calderon-Hernandez
Cielo Cinthya Calderon-Hernandez
TVTatiana Vanessa Villavicencio-Escudero
Tatiana Vanessa Villavicencio-Escudero

6 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FRFernando M. Runzer-Colmenares
Fernando M. Runzer-Colmenares
NCNelson Luis Cahuapaza-Gutierrez
Nelson Luis Cahuapaza-Gutierrez
CCCielo Cinthya Calderon-Hernandez
Cielo Cinthya Calderon-Hernandez
MBMariam Miyanay Umeres Bravo
Mariam Miyanay Umeres Bravo
Background/Objectives: Vaccination against respiratory viruses—such as respiratory syncytial virus (RSV), pneumococcal disease, influenza, and COVID-19—may reduce the risk of adverse outcomes in older adults with cardiovascular disease. This study conducted a scoping review of the effects of respiratory vaccines in older adults with cardiovascular disease. Methods: We included studies evaluating adults aged ≥60 years with cardiovascular disease who received different types of respiratory vaccines. Eligible designs comprised clinical trials, observational cohort studies, and other relevant studies. Editorials, commentaries, and non-original publications were excluded. A comprehensive and targeted literature search was conducted in PubMed, Scopus, EMBASE, and Web of Science from database inception through January 2026. Results: A total of 26 studies were included, encompassing 1,782,787 adults aged ≥60 years with cardiovascular disease who received various respiratory vaccines. RSV vaccines were associated with a lower incidence of cardiorespiratory hospitalization and stroke among vaccinated individuals. Pneumococcal vaccines showed that sequential dual vaccination strategies were associated with a lower risk of cardiovascular events. Influenza vaccination was associated with improved cardiovascular outcomes, lower mortality, and reduced adverse events. COVID-19 vaccines were associated with reductions in mortality and hospitalizations. These benefits are particularly relevant in an older population with a high burden of comorbidities; therefore, complete vaccination schedules, including booster doses, should be considered a central strategy for prevention and comprehensive management in this high-risk group. Conclusions: Vaccination against respiratory viruses in older adults with cardiovascular disease demonstrates an overall favorable/acceptable profile of efficacy and safety, with reductions in mortality, hospitalizations, and cardiovascular events, without a significant increase in serious adverse events.